Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: Chinese investment in Australian healthcare hits A$5.5 billion

Not having featured before 2015, Chinese investment in Australia’s healthcare sector has surged over the past three years. It has reached A$5.5 billion (US$4.5 billion) across 16 completed deals, according to a new report from KPMG and The University of Sydney Business School.

The report, Demystifying Chinese Investment in Australian Healthcare, which covers investments into Australia made by entities from China through m&a and joint ventures from 2015 to 2017, found that investment has been concentrated in the health supplement and medical treatment sectors in Australia. To date there has been no significant investment in pharmaceuticals, biotechnology or aged care.

According to the report, A$2.55 billion was invested in 2015, A$1.35 billion in 2016 and A$1.58 billion last year through several very large deals, including the A$930 million acquisition of hospital operator Healthe Care in 2015 and the acquisition of Swisse Wellness for more than A$1.5 billion across 2015 and 2016. Major deals last year included the A$800 million investment in Ansell’s Sex Wellness Division by Humanwell Healthcare and CITIC capital, and the A$337million investment in PRP Diagnostic Imaging by Hengkang Medical Group.

Advantageous international trade agreements combined with progressive domestic initiatives such as the Commonwealth Government’s Medical Research and Innovation Strategy and the National Innovation and Science Agenda are improving Australia’s comparative advantage in advanced health sector industries and helping drive further investment attraction.

Australia is doing well relative to many other countries. By comparison, Chinese investment into US health, pharma and biotech for the three year period reached US$4.7 billion.

According to report co-author, Doug Ferguson, head of Asia and international markets at KPMG Australia, the country’s success in attracting investment is due to Chinese companies’ seeking what he calls the complete Australia package. "Chinese investors have really shifted their investment interests to Australia’s high-tech, high quality health products and services sector in the last three years,” he said. “Australia presents a range of country-specific advantages that include advanced technology application, quality care facilities, strong management systems and the clean, green and healthy image for Aussie branded exports back to China. As China’s aged care industry develops and its medical treatment sector matures there will be a greater need for these qualities and more demand for the businesses providing them. There’s still a long way to go," he explained.

China’s central government’s “Healthy China 2030” plan provides a very clear framework for the country’s health sector development priorities. China’s healthcare spending is expected to grow by 8.1% a year over the next five years, representing a big opportunity for Australia’s health sector. “The patterns that are emerging in China’s domestic healthcare sector are likely to strengthen investment demand in the coming years as healthcare assets become a key component of many Chinese investor’s portfolios,” said Jenny Yao, KPMG China’s head of healthcare in Beijing.

Rather than general health services, many Chinese companies seek to invest in specialist services, such as oncology, radiology, ophthalmology, IVF, and aged care. These services are replicable in the Chinese market and customised to fit the specific needs of China’s middle-to-high end consumer markets. Australian healthcare brands have an initial advantage in China due to their reputation for high quality products with consumers.

The report predicts that investment will broaden across all sectors in the short-to-medium term. The patterns that have emerged in Chinese healthcare investment so far will likely strengthen in the coming years as healthcare assets become a key component of many Chinese investors’ portfolios.

The introduction of Chinese policies to establish a public/private healthcare system built on "big health" presents an opportunity for Australian companies to share their expertise and participate profitably in the industry’s transition and growth.

“For Australian companies, Chinese investment presents an opportunity to access capital and new markets with new supply chains with established local partners. The outcome of increased investment will be a highly competitive Australian healthcare sector that can accelerate exports as well as continue private sector investment in research and improve technological capabilities,” said Ferguson.

Posted on: 31/01/2018 UTC+08:00


News

China Isotope & Radiation, which manufactures diagnostic and therapeutic radiopharmaceuticals products, has launched its HK$1.9 billion (US$247 million) IPO on the Hong Kong Stock Exchange.
Malaysian multinational PRG Holdings has extended the deadline for its M$18.3 million (US$4.6 million) acquisition of O&G focused private medical services provider Roopi Medical Centre.
Hong Kong-listed WuXi Biologics, a subsidiary of WuXi PharmaTech, has started the construction of an integrated biologics conjugate solution centre in Wuxi city.
RHT Health Trust, the first business trust listed on the Singapore stock exchange with a portfolio comprising healthcare assets in India, has confirmed that it has received all outstanding amounts due from India’s Fortis Healthcare for the past financial year.
Shares in Ramsay Health Care, Australia’s largest private hospital operator, slumped today after the group cut earnings guidance. It flagged up “onerous lease provisions” and asset writedowns on a number of its hospitals in the UK.
Following Monday’s 5.9 magnitude earthquake which struck Osaka, Parkway Life REIT, which is owned by IHH Healthcare, has confirmed that its Japan asset managers, operators and residents at its Japan healthcare facilities are accounted for with no reported injuries.
Singapore-listed property developer Perennial Real Estate has incorporated a new subsidiary in China. Perennial (Shanghai) Health Management will be involved in the management of its healthcare business in Shanghai.
Yestar Aesthetic Medical Group, the second largest private aesthetic medical institution group in China, is planning an IPO on Hong Kong’s mainboard. CICC is sole sponsor to the deal.



Analysis

Aon’s inaugural Asia Healthcare Trends Report 2017/18 shows that although Hong Kong has a lower medical inflation rate than the average in APAC, it is the highest in Greater China.
Out of date and unsecure fax machines are still being used to share patient information between healthcare providers in Australia. Not only do fax machines cause frustration for healthcare providers trying to communicate with each other, they can also cause patient harm.
Health and well-being programmes are fragmented and do not meet the needs of stressed Asia workforces, finds Willis Towers Watson. By and large, employers in Asia still miss the mark when it comes to their health and well-being benefits, with many employees feeling that their needs are not met, according to research from the global advisory, broking and solutions company.
According to a survey of biopharma companies by L.E.K. Consulting, the majority of firms from Western Europe or the US are interested in China, specifically those at Phase 2 or later development.
Sara Jost, global healthcare industry lead at BlackBerry, explains that putting the systems and procedures in place to deliver a healthy and secure digital healthcare system will protect patient health information and support medical innovation.
Joseph Soon, global digital director at Bupa, explains why industry players must stay agile in the market and act fast to take every opportunity the digital age has to offer.
The Asia-Pacific (APAC) healthcare industry is undergoing rapid transformation with a dramatic shift in consumer behaviour and expectations, opening up growth opportunities across diagnostics, regenerative medicine, medical tourism and digital health.
Tan Chorh Chuan, executive director at the Office for Healthcare Transformation and chief health scientist at the Ministry of Health in Singapore, explains why population health improvement has to become a crucial area of focus.
my images

Podcasts

HealthInvestor Asia twitter feed